• Publications
  • Influence
N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins.
It is concluded that AGEs are largely glycoxidation products and that CML is a major AGE recognized in tissue proteins by polyclonal antibodies to AGE proteins.
Pharmacokinetics of anti‐D IgG in pregnant RhD‐negative women
Assessment of the pharmacokinetics of anti‐D IgG in pregnant Rhesus D‐negative women after intramuscular and intravenous administration of 300 μg of Rhophylac finds no significant differences between the two doses.
A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes.
Despite the variation in clearance rates there was no evidence of anti-RhD alloantibodies in any of the subjects at +6 months after the RBC challenge, and Interestingly, RhD-positive RBC clearance rates were strongly associated with Fcgamma receptor IIA and FcGammaRIIA but not with F cgammaIIIB polymorphisms.
Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rhFVIII) in adults with severe haemophilia A
Haemophilia A is treated with FVIII, either prophylactically or on demand. Prophylaxis is the gold standard in children and evidence is accumulating in adults.
Safety and Efficacy of Privigen®, a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in Patients with Primary Immunodeficiencies
Privigen® is well tolerated and effective for the treatment of primary immunodeficiency and may be related to study drug, possibly or probably related toStudy drug.
Carimune NF Liquid is a Safe and Effective Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency Diseases
Carimune NF Liquid, a ready-to-use, high-concentration, liquid immunoglobulin preparation is safe and effective, and there were no serious drug-related adverse events or acute serious bacterial infections.
Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulin.
The results suggest that Rhophylac 300 given intravenously or intramuscularly is safe and efficacious in preventing rhesus (D) immunisation.
Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
The activated partial thromboplastin time test seems to be well suited to monitor the anticoagulant effect of recombinant hirudin because the dose effect is linear up to 0.5 mg/kg of subcutaneous CGP 39393.
Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).
Recombinant hirudin CGP 39393 appears to be a weak allergen that is safe in fully immunocompetent subjects, including those with a history of previous allergies and high levels of total IgE.
Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety
Nuwiq® [human cell line‐derived recombinant factor VIII (human‐cl rhFVIII)] is a new generation rFVIII protein, without chemical modification or fusion to any other protein, produced in a human cell